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ABSTRACT
The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been recently proposed to pre-
dict the probability of nonrelapse mortality (NRM) and overall survival (OS) in allogeneic HCT recipients while
taking into account any pretransplant comorbidity.We tested the validity of theHCT-CI in a cohort of 373 adult
HCT recipients (184matched-related donor and 189 unrelated umbilical cord blood) who received amyeloabla-
tive (N 5 150) or nonmyeloablative (N 5 223) conditioning regimen. HCT-CI scores of 0, 1, 2, and $3 were
present in 58 (16%), 56 (15%), 64 (17%), and 195 (52%) patients, respectively. Pulmonary conditions were
the most common comorbidity. Cumulative incidence of NRM at 2 years was 10%, 20%, 24%, and 28% for
HCT-CI scores of 0, 1, 2, and $3, respectively (P 5 .01). The corresponding probability of OS at 2 years was
72%, 67%, 51%, and 48%, respectively (P\ .01). On multivariate analyses adjusted for recipient age, disease
risk, donor source, and conditioning regimen intensity, the relative risks for NRM for HCT-CI scores of 1, 2,
and $3 (compared to a score of 0) were 2.0 (95% confidence intervals, 0.8–5.3), 2.6 (1.0–6.7), and 3.2 (1.4-
7.4), respectively. The risks for overall mortality were 1.2 (0.6-2.1), 2.0 (1.1-3.4), and 2.1 (1.3-3.3), respectively.
In subgroup analyses, theHCT-CI score did not consistently predict NRM andOS among different donor sour-
ces and conditioning regimens. The HCT-CI, although a useful tool for capturing pretransplant comorbidity
and risk-assessment, needs to be further validated prior to adopting it for routine clinical use.
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Major advances in the field of allogeneic hemato-
poietic cell transplantation (HCT) have occurred in
the past few decades. However, this procedure can still
be associated with significant complications. The ad-
vent of nonablative conditioning regimens has led to
an increasing use of transplantation in older patients
and in patients with comorbidities. Estimating the
risk of treatment-related morbidity and mortality
(TRM), especially in patients with coexisting comor-
bidities, is a frequent challenge. A reliable estimation
of this risk has important implications for counselingand determining the candidacy of a given patient for al-
logeneic HCT. The HCT-specific comorbidity index
(HCT-CI) has been recently proposed and, using
a weighted scoring system, predicts the probability of
posttransplant nonrelapse mortality (NRM) and overall
survival (OS) while taking into account any pretrans-
plant comorbidities [1]. Early retrospective studies
have shown the HCT-CI to be useful for predicting
NRM in allogeneic HCT recipients [2,3]. However,
this tool has not been independently validated by other
transplant centers and has not been explored in recipi-
ents of unrelated umbilical cord blood (UCB). We985
986 N. S. Majhail et al.conducted a retrospective cohort study to determine
the validity of this score in a large cohort of matched
related donor (MRD) and UCB transplant recipients.
METHODS
Patients and Treatment
This analysis included consecutive adult patients
who received anMRDorUCBHCT at our institution
between 2000 and 2005. Nineteen patients who re-
ceived a matched unrelated donor HCT during this
time period were excluded from this analysis. Of the
441 eligible patients, 68 did not have adequate data
regarding pretransplant comorbidities available to ob-
tain the HCT-CI score. Therefore, the final study co-
hort consisted of 373 patients, and included 184 MRD
and 189 UCB transplant recipients who were trans-
planted with either a myeloablative (MA, N 5 150)
or nonmyeloablative (NMA, N 5 223) conditioning
regimen (Table 1). There was no significant difference
in the probability of NRM and OS between the 68 ex-
cluded patients and those included in this analysis. All
patients were transplanted on protocols approved by
our institutional review board.
Eligibility criteria for HCT using NMA condi-
tioning included older age ($55 years for MRD and
$45 years for UCB), presence of significant comorbid-
ity (serious organ dysfunction, invasive mold infection
within 4 months before transplantation, or Karnofsky
performance score of 50-60) or extensive prior therapy
(.12 months of alkylator-based chemotherapy, .6
months of alkylator-based chemotherapy and exten-
sive radiation, or history of autologous transplanta-
tion). Patients received UCB as a graft source if they
had no HLA-compatible related donors. Our UCB se-
lection criteria for adults have been previously pub-
lished, and allow the use of 2 UCB units to optimize
cell dose, if necessary [4-6]. UCB grafts were matched
at least 4 of 6HLA-A,-B (antigen level) and -DRB1 (al-
lele level) to the recipient, and in patients receiving 2
UCB units, also to each other. TheMA andNMA con-
ditioning and graft-versus-host disease (GVHD) pro-
phylaxis regimens used at our institution have been
described previously [5,7-9]. The dose of total body
irradiation (TBI) was 1320 cGy (165 cGy twice daily
4 days) in MA and 200 cGy (single fraction) in
NMA regimens.
Data Collection
Transplant-related and outcome data was re-
trieved from our Blood and Marrow Transplant Pro-
gram Database, which prospectively collects these
data for all patients receiving HCT at our institution.
Data regarding pretransplant comorbidities was ex-
tracted from a detailed review of medical charts. Cause
of death information was obtained from our database
that routinely records the primary cause of death asassigned by the treating physician at the time of patient
death using uniform criteria.
Pretransplantation comorbidities were scored ret-
rospectively for all patients using the HCT-CI [1].
The comorbidities capturedby this tool include cardiac
disorders, cerebrovascular disease, diabetes, altered he-
patic function, infection, inflammatory bowel disease,
obesity, peptic ulcer disease, psychiatric disturbance,
pulmonary abnormalities, renal insufficiency, and
rheumatologic disorders. Scores are assigned to various
comorbidities based on their severity and a final com-
posite score is then calculated and patients can be
assigned to 1 of 3 risk groups: low risk (score 0), inter-
mediate risk (score 1-2), and highrisk (score $ 3).
A second investigator independently reviewed
medical charts of 110 randomly selected patients and
assigned HCT-CI scores. There was good agreement
between the scores assigned by the 2 investigators
(Kappa coefficient 0.87; 95% confidence intervals
[CI], 0.81-0.95). No specific domain was identified
where consistent disagreement occurred between the
2 investigators.
Statistical Analysis
The primary endpoints for this analysis were the
cumulative incidence ofNRMat 1 year and probability
of OS at 2 years after allogeneic HCT. NRM was de-
fined as death following HCT without disease pro-
gression or relapse. Demographic variables for the
patient cohorts were compared across the 2 groups us-
ing the chi-square test for categoric variables and the
Wilcoxon’s rank sum test for continuous variables.
Probabilities of NRM were calculated using cumula-
tive incidence curves to accommodate competing risks
[10]. Univariate probabilities ofOSwere calculated us-
ing the Kaplan-Meier estimator [11]. Cox regression
models were built to determine the independent effect
of HCT-CI score on survival [12], and the propor-
tional hazards models of Fine and Gray [13] were
used to determine the independent effect of HCT-
CI score on NRM. All factors were tested for the pro-
portional hazards assumption. The primary objective
was to compare outcomes according to stem cell
source and HCT-CI score; these variables were in-
cluded in all models and were adjusted for age at trans-
plant, conditioning regimen intensity, and disease risk.
There were no significant interactions between stem
cell source and any other variables, including condi-
tioning regimen intensity. All P-values are 2 sided.
Analyses were performed using SAS software, version
9.1 (SAS Institute, Cary, NC).
RESULTS
HCT-CI Score
The overall distribution of the HCT-CI score was
similar in the 2 groups (Table 1). For the whole cohort,
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Factors
Matched
Related Donor
Umbilical
Cord Blood P-Value
Total 184 189
Median age at
transplant (range),
years
48 (18-66) 45 (18-69) .02
Age at transplant
\50 years 104 (57%) 117 (62%) .29
$50 years 80 (43%) 72 (38%)
Sex
Male 108 (59%) 117 (62%) .53
Female 76 (41%) 72 (38%)
Karnofsky performance
status
.99
$90 136 (74%) 141 (75%)
\90 37 (20%) 37 (19%)
Missing 11 (6%) 11 (6%)
Median HCT-CI score
(range)
3 (0-11) 3 (0-9) .57
HCT-CI score .27
0 26 (14%) 32 (17%)
1 22 (12%) 34 (18%)
2 36 (20%) 28 (15%)
3 44 (24%) 34 (18%)
4 30 (16%) 25 (13%)
5 12 (7%) 18 (10%)
$6 14 (8%) 18 (10%)
Diagnosis \.01
Acute myelogenous
leukemia
32 (17%) 65 (34%)
Non-Hodgkin
lymphoma
52 (28%) 39 (21%)
Acute lymphoblastic
leukemia
14 (8%) 27 (14%)
Myelodysplastic
syndrome
15 (8%) 15 (8%)
Hodgkin lymphoma 15 (8%) 12 (6%)
Multiple myeloma 23 (13%) 4 (2%)
Chronic myelogenous
leukemia
9 (5%) 14 (7%)
Chronic lymphocytic
leukemia
11 (6%) 6 (3%)
Severe aplastic
anemia
6 (3%) 4 (2%)
Myeloproliferative
diseases
3 (2%) 2 (1%)
Other 4 (2%) 1 (\1%)
Disease risk* .23
Standard 39 (21%) 50 (26%)
High 145 (79%) 139 (74%)
Donor source
Bone marrow 10 (5%) –
Peripheral blood stem
cells
174 (95%) –
Single umbilical cord
blood
– 38 (20%)
Double umbilical cord
blood
– 151 (80%)
HLA match† \.01
6/6 176 (96%) 10 (5%)
5/6 8 (4%) 40 (21%)
4/6 0 139 (74%)
Previous transplant 34 (18%) 33 (17%) .80
Conditioning regimen \.01
(Continued )scores of 0, 1, 2, and $3 were present in 58 (16%), 56
(15%), 64 (17%), and 195 (52%) patients, respectively.
The distribution of HCT-CI scores was also compara-
ble between the 2 conditioning regimens. Scores of 0,
1, 2, and $3 were present in 28 (19%), 26 (17%), 27
(18%), and 69 (46%) MA recipients compared to 30
(14%), 30 (14%), 37 (17%), and 116 (52%) in NMA
recipients, respectively (P 5 .39). The distribution of
scores among the donor and conditioning regimen
groups combined (MA MRD, NMA MRD, MA
UCB, and NMA UCB) was also comparable.
The distribution of individual comorbidities that
define theHCT-CI score is shown in Figure 1. Pulmo-
nary conditions were themost common comorbidity in
our cohort (231 [59%] patients). These included 141
patients with moderate and 90 patients with severe
pulmonary comorbidity. Other common comorbid-
ities were hepatic (23%), psychiatric (20%), cardiac
(14%), and obesity (13%). The distribution of various
comorbidities between recipients of MRD and UCB
was comparable. Compared to MA HCT recipients,
a significantly larger proportion of patients undergoing
NMAHCT had cardiac comorbidity (8% versus 18%,
P\ .01) and infection (3% versus 10%, P 5 .01); the
Table 1. (Continued )
Factors
Matched
Related Donor
Umbilical
Cord Blood P-Value
Myeloablative 88 (48%) 62 (33%)
Cy/TBI 73 1
Cy/Flu/TBI 1 59
Bu/Cy 7 2
Other 7 0
Nonmyeloablative 96 (52%) 127 (67%)
Cy/Flu/TBI 45 70
Cy/Flu/TBI/ATG 13 37
Bu/Flu/TBI 22 20
Other 16 0
GVHD prophylaxis
regimen‡
\.01
CSA/MMF 95 (52%) 188 (99%)
CSA/MTX 84 (46%) 0
Other 5 (2%) 1 (\1%)
Median followup
(range), years
3.0 (1.0-7.0) 2.4 (1.0-6.7)
HCT-CI indicates hematopoietic cell transplantation comorbidity
index; HLA, human leukocyte antigen; Cy, cyclophosphamide;
TBI, total body irradiation; Flu, fludarabine; Bu, busulfan;
ATG, antithymocyte globulin; CSA, cyclosporine; MMF, myco-
phenolate mofetil; MTX, methotrexate, GVHD, graft-versus-
host disease, CSA, cyclosporine; MMF, mycophenolate mofetil;
MTX, methotrexate.
*Standard-risk disease included acute leukemia in first complete re-
mission, chronic myeloid leukemia in first chronic phase, myelodys-
plastic syndrome-refractory anemia, and nonmalignant hematologic
disorders; all other diagnoses were categorized as high risk disease.
†Worst match for double umbilical cord blood transplants.
‡Amongmatched related donor transplants,myeloablative recipients
received CSA/MTX, whereas nonmyeloablative recipients received
CSA/MMF.
988 N. S. Majhail et al.frequencies of specific comorbidities between the 2
conditioning groups was otherwise comparable.
NRM and OS
Figure 2 shows cumulative incidences of NRM for
each donor source and conditioning regimen. For the
whole cohort, 2-year NRM rates were 10% (95% CI:
2%-18%), 20% (10%-30%), 24% (14%-34%), and
28% (22%-34%) for HCT-CI scores of 0, 1, 2, and
$3, respectively (P 5 .01). Within the subgroups of
donor source and conditioning regimen, there was
no significant difference in the univariate probabilities
of NRM for recipients of MRD, UCB, or NMA con-
ditioning for different HCT-CI scores. For patients
receiving MA conditioning, the cumulative incidenceof NRM at 2 years for the 4 scores was 4%, 19%,
30%, and 30%, respectively (P 5 .03).
Probabilities of OS are shown in Figure 3. For the
whole cohort, probabilities of OS at 2 years for HCT-
CI scores of 0, 1, 2, and$3 were 72% (95% CI: 61%-
83%), 67% (55%-79%), 51% (39%-63%), and 48%
(41%-55%), respectively (P\ .01). On subgroup anal-
ysis, OS by HCT-CI score did not differ significantly
for recipients of UCB or NMA conditioning. Two-
year OS rates for the 4 scores in MRD recipients was
81%, 63%, 50%, and 49% (P5 .03), and for MA con-
ditioning recipients was 82%, 69%, 48%, and 53%
(P 5 .02), respectively.
In multivariate analysis for the whole cohort,
HCT-CI scores of 2 and $3 were independentFigure 1. Distribution of comorbidities in MA (N 5 150) and NMA (N 5 223) hematopoietic cell transplant recipients (Y-axis represents
percentage of patients within the cohort with specific comorbidities).
HCT Comorbidity Index in UCB and MRD Transplantation 989Figure 2. Cumulative incidence of NRM by conditioning regimen and donor source for HCT-CI scores (1-year rates are indicated in brackets;
MRD, matched related donor; UCB, umbilical cord blood; MA, myeloablative conditioning; NMA, nonmyeloablative conditioning).predictors of NRM (Table 2). Similarly, scores of 2
and $3 also predicted for OS. In analysis limited to
MRD recipients, the relative risks (RR) of NRM did
not differ significantly between the 4 HCT-CI score
categories. Among UCB recipients, the HCT-CI
score again did not have an independent impact on
NRM. In multivariate analysis for OS within the
MRD cohort, HCT-CI scores of 2 (RR 2.5 [95% CI,
1.1-5.6]) and $3 (RR 2.4 [1.2-4.9]) significantly influ-
enced survival, whereas a score of 1 did not (RR 1.7
[0.4-4.1]). Within the UCB cohort, only a score of
$3 (RR 1.9 [1.0-3.6]) was significantly related with
OS, wherease no association was observed for scores
of 1 (RR 1.0 [0.4-2.2]) or 2 (RR 1.6 [0.7-3.4]).
Combining scores of 1 and 2 as an ‘‘intermediate-
risk’’ group as described in its initial description did
not increase the sensitivity of the HCT-CI for NRM
or OS. For scores of 0, 1-2, and$3, the cumulative in-
cidence of NRM at 2 years was 10% (95% CI: 2%-
18%), 22% (15%-29%), and 28% (22%-34%) (P\
.01) and the probability of OS at 2 years was 72%
(61%-83%), 59% (50%-68%), and 48% (41%-55%)
(P\ .01), respectively. In multivariate analyses (com-
pared to score of 0) the RR of NRM for scores of
1-2 and $3 was 2.3 (95% CI: 1.0-5.5) and 3.2 (1.4-
7.4), respectively. The corresponding risks for OS
were 1.6 (0.9-2.6) and 2.1 (1.3-3.3).Because preexisting pulmonary conditions can
significantly contribute to HCT-associated morbidity
and mortality and constituted the most common co-
morbidity in our cohort (59% patients), we estimated
the univariate probabilities of NRM for individual
scores for pulmonary comorbidity as defined by the
HCT-CI. The cumulative incidence of NRM at 1
year was 13% (95% CI: 8%-18%) for patients with
no pulmonary comorbidity, 23% (16%-30%) for
moderate pulmonary comorbidity, and 32% (22%-
42%) for severe pulmonary comorbidity (P\ .01).
Cause of Death
Causes of death within 1 year posttransplant strat-
ified by HCT-CI scores are displayed in Table 3.
Overall, relapse was the most common primary cause
of death within the first year (14%), and was followed
by organ failure or toxicity (8%), infections (6%), and
GVHD (5%). For HCT-CI scores of 0, 1, 2, and $3,
death could be attributed to organ failure or toxicity in
3%, 5%, 9%, and 10% of patients, respectively.
DISCUSSION
Considering comorbidities during pretransplant
risk assessment is a clinical challenge. The HCT-CI
combines important comorbidities with varying
990 N. S. Majhail et al.Figure 3. Probability of OS by conditioning regimen and donor source for HCT-CI scores (2-year rates are indicated in brackets; MRD,
matched related donor; UCB, umbilical cord blood; MA, myeloablative conditioning; NMA, nonmyeloablative conditioning).impact on treatment related morbidity and mortality
into a single score and is a first step toward incorporat-
ing comorbidities in clinical decision analysis for trans-
plantation and for risk adjustment for clinical trials.We found the HCT-CI to be a relatively simple and
reliable tool for capturing pretransplant comorbid-
ities. However, in our experience, it did not predict
NRM and OS as robustly as has been reported inTable 2. Multivariate Analysis for Nonrelapse Mortality and Overall Surviva
Nonrelapse Mortality Overall Survival
Factor N RR (95% CI) P-value RR (95% CI) P-value
HCT-CI score
0* 58 1.0 1.0
1 56 2.0 (0.8-5.3) .17 1.2 (0.6-2.1) .64
2 64 2.6 (1.0-6.7) .05 2.0 (1.1-3.4) .01
$3 195 3.2 (1.4-7.4) \.01 2.1 (1.3-3.3) \.01
Donor source
Matched related donor* 184 1.0 1.0
Umbilical cord blood 189 1.2 (0.8-1.8) .49 1.1 (0.8-1.5) .49
Age at transplant
\50 years* 221 1.0 1.0
$50 years 152 1.1 (0.7-1.8) .72 1.3 (0.9-1.8) .15
Disease risk†
Standard* 89 1.0 1.0
High 284 1.2 (0.7-2.0) .52 1.3 (0.9-1.9) .13
Conditioning
Myeloablative* 150 1.0 1.0
Nonmyeloablative 223 0.8 (0.5-1.4) .49 1.0 (0.7-1.4) .87
HCT-CI indicates hematopoietic cell transplantation comorbidity index; RR, relative risk; CI, confidence intervals.
*Reference value.
†Standard-risk disease included acute leukemia in first complete remission, chronicmyelogenous leukemia in first chronic phase,myelodysplastic
syndrome-refractory anemia, and nonmalignant hematologic disorders; all other diagnoses were categorized as high-risk disease.
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trend toward worsening outcomes with each incre-
ment in the HCT-CI score, this was not consistently
noted among different donor sources and conditioning
regimens.
This limited generalizability of the HCT-CI in
our patient population could be attributed to specific
characteristics of our study cohort. First, our study in-
cluded a large proportion of patients who received
UCB as a donor source. Recent analyses have reported
a lower risk of acute and chronic GVHD (aGVHD,
cGVHD) UCB recipients [14-16], which could be as-
sociated with a lower risk of NRM. Compared to pub-
lished series, our study cohort also had a larger
proportion of patients with comorbidities that are cap-
tured by the HCT-CI. Only 16% of our patients had
no comorbidities (score of 0) compared to 21% to
51% in other reports [1-3,17,18]. Last, the prevalence
of comorbidities was also different in our population.
For instance, 59% of our patients had pulmonary co-
morbidity compared to 33% in the initial report of
the HCT-CI by Sorror et al. [1]. Comorbidities in-
volving different organ systems could have a differen-
tial impact on the risk of NRM after transplantation.
Although the HCT-CI has been recently investi-
gated as a predictor of outcomes in disease-specific
analyses [3,18], the ideal tool for capturing pre-HCT
comorbidities and integrating them in clinical decision
making should be valid across conditioning regimens,
donor sources, and transplant practices. The HCT-CI
has the potential to be such a universal tool if it could
be improved to increase its generalizability. Impact of
inclusion of other predictors for NRM and OS such as
recipient age and performance status on its sensitivity
needs to be explored. Its validity also needs to be tested
and confirmed in other transplant centers because var-
iations in the prevalence of comorbidities in different
patient populations could affect its performance. Fur-
ther refinement of the score by exclusion of comorbid-
ities with low prevalence and little impact on NRM
Table 3. Causes of Death within 1-Year Posttransplant for HCT-CI
Scores of 0, 1, 2, and $3
HCT-CI Score
Primary Cause of Death 0 N (%) 1 N (%) 2 N (%) $3 N (%)
Number of patients 58 56 64 195
Relapse 4 (7%) 5 (9%) 10 (16%) 32 (16%)
Organ failure/toxicity 2 (3%) 3 (5%) 6 (9%) 19 (10%)
Graft-versus-host
disease
0 3 (5%) 6 (9%) 11 (7%)
Infection 2 (3%) 3 (5%) 1 (2%) 17 (9%)
Hemorrhage 0 0 3 (5%) 3 (2%)
Graft failure 0 2 (4%) 0 1 (\1%)
Second cancer 1 (2%) 0 0 1 (\1%)
Unknown 1 (2%) 1 (2%) 1 (2%) 0
HCT-CI indicates hematopoietic cell transplantation comorbidity
index.could also increase its sensitivity. Its validity also needs
to be tested in pediatric HCT recipients.
Our study has the typical limitations of a retrospec-
tive cohort study. Furthermore, the overall sample size
and number of events within specific subgroups inves-
tigated was relatively small. Although clinical and lab-
oratory information needed to calculate the HCT-CI
score was abstracted from medical charts, most of
these data are routinely collected during pretransplant
workup at our institution. Also, we do not anticipate
changes in transplant techniques or supportive care
to have had a significant impact on outcomes given
the contemporary nature of our study cohort.
In conclusion, the HCT-CI is a novel and simple
tool that considers the presence or absence of pretrans-
plant comorbidities to predict the risk of death because
of transplant-related complications. It has the poten-
tial for widespread applicability both in clinical prac-
tice and in clinical trials. However, prior to its
routine use, its validity and generalizability has to be
further investigated, especially in prospective multi-
center studies. Its sensitivity could be further increased
by including other potential risk factors such as age
and excluding comorbidities that may be less prevalent
and less important in transplant recipients.
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